Trial Profile

A randomized, double blind, placebo-controlled single ascending dose study of LY03003 in healthy volunteers

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 15 Mar 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rotigotine (Primary)
Indications Parkinson's disease
Focus Adverse reactions; Pharmacokinetics
Acronyms 03003SAD
Sponsors Luye Pharma Group

Most Recent Events

15 Mar 2016 New trial record
11 Mar 2016 Data from this and another phase I trial (CTP 700241160) will support a New Drug Application (NDA) via a 505(b)(2) pathway to the US FDA for LY03003, according to a Luye Pharma Group Ltd. media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com